Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
Tóm tắt
The incidence of esophagogastric cancer is rapidly rising, but only a minority of patients derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 antibodies are standard treatments. To identify predictive biomarkers of drug sensitivity and mechanisms of resistance, we implemented prospective tumor sequencing of patients with metastatic esophagogastric cancer. There was no association between homologous recombination deficiency defects and response to platinum-based chemotherapy. Patients with microsatellite instability–high tumors were intrinsically resistant to chemotherapy but more likely to achieve durable responses to immunotherapy. The single Epstein–Barr virus–positive patient achieved a durable, complete response to immunotherapy. The level of ERBB2 amplification as determined by sequencing was predictive of trastuzumab benefit. Selection for a tumor subclone lacking ERBB2 amplification, deletion of ERBB2 exon 16, and comutations in the receptor tyrosine kinase, RAS, and PI3K pathways were associated with intrinsic and/or acquired trastuzumab resistance. Prospective genomic profiling can identify patients most likely to derive durable benefit to immunotherapy and trastuzumab and guide strategies to overcome drug resistance.
Significance: Clinical application of multiplex sequencing can identify biomarkers of treatment response to contemporary systemic therapies in metastatic esophagogastric cancer. This large prospective analysis sheds light on the biological complexity and the dynamic nature of therapeutic resistance in metastatic esophagogastric cancers. Cancer Discov; 8(1); 49–58. ©2017 AACR.
See related commentary by Sundar and Tan, p. 14.
See related article by Pectasides et al., p. 37.
This article is highlighted in the In This Issue feature, p. 1
Từ khóa
Tài liệu tham khảo
Cancer Genome Atlas Research Network, 2017, Integrated genomic characterization of oesophageal carcinoma, Nature, 541, 169, 10.1038/nature20805
Cancer Genome Atlas Research Network, 2014, Comprehensive molecular characterization of gastric adenocarcinoma, Nature, 513, 202, 10.1038/nature13480
Cristescu, 2015, Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes, Nat Med, 21, 449, 10.1038/nm.3850
Secrier, 2016, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance, Nat Genet, 48, 1131, 10.1038/ng.3659
Elimova, 2017, It is time to stop using epirubicin to treat any patient with gastroesophageal adenocarcinoma, J Clin Oncol, 35, 475, 10.1200/JCO.2016.69.7276
Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X
Muro, 2016, Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial, Lancet Oncol, 17, 717, 10.1016/S1470-2045(16)00175-3
Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, New Engl J Med, 372, 2509, 10.1056/NEJMoa1500596
Fuchs, 2017, KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer, J Clin Oncol, 35, 4003, 10.1200/JCO.2017.35.15_suppl.4003
Kang, 2017, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 31827
Zehir, 2017, Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med, 23, 703, 10.1038/nm.4333
Niu, 2014, MSIsensor: microsatellite instability detection using paired tumor-normal sequence data, Bioinforma, 30, 1015, 10.1093/bioinformatics/btt755
Chakravarty, 2017, OncoKB: a precision oncology knowledge base, JCO Precis Oncol, 10.1200/PO.17.00011
Ohtsu, 2011, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study, J Clin Oncol, 29, 3968, 10.1200/JCO.2011.36.2236
Mirza, 2016, Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, N Engl J Med, 375, 2154, 10.1056/NEJMoa1611310
Telli, 2016, Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer, Clin Cancer Res, 22, 3764, 10.1158/1078-0432.CCR-15-2477
Smyth, 2017, Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial, JAMA Oncol, 3, 1197, 10.1001/jamaoncol.2016.6762
Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N Engl J Med, 375, 819, 10.1056/NEJMoa1604958
Ross, 2017, Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay, J Mol Diagn, 19, 244, 10.1016/j.jmoldx.2016.09.010
Gomez-Martin, 2013, Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab, J Clin Oncol, 31, 4445, 10.1200/JCO.2013.48.9070
Lee, 2015, The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer, Sci Rep, 5, 9289, 10.1038/srep09289
Kim, 2014, Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma, J Clin Invest, 124, 5145, 10.1172/JCI75200
Castiglioni, 2006, Role of exon-16-deleted HER2 in breast carcinomas, Endocr Relat Cancer, 13, 221, 10.1677/erc.1.01047
Turpin, 2016, The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment, Oncogene, 35, 6053, 10.1038/onc.2016.129
Tagliabue, 2009, The HER2 World: better treatment selection for better outcome, J Natl Cancer Inst Monogr, 2011, 82, 10.1093/jncimonographs/lgr041
Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095
Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088
AACR Project GENIE Consortium, 2017, AACR project GENIE: powering precision medicine through an international consortium, Cancer Discov, 7, 818, 10.1158/2159-8290.CD-17-0151
Gulley, 2017, Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial, Lancet Oncol, 18, 599, 10.1016/S1470-2045(17)30240-1
Cheng, 2015, Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology, J Mol Diagn, 17, 251, 10.1016/j.jmoldx.2014.12.006
Chang, 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity, Nat Biotechnol, 34, 155, 10.1038/nbt.3391
Shen, 2016, FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing, Nucleic Acids Res, 44, e131, 10.1093/nar/gkw520